In an interview with Pharm Exec deputy editor Don Tracy, Carlos Doty, vice president and medical head of AstraZeneca’s U.S. oncology business, discusses the history of PARP inhibitors and Lynparza in cancer treatment.
AstraZeneca’s US Vice President of Oncology Medical Affairs discusses impact of PARP inhibitors on cancer treatment
Leave a comment
